In the era of next generation sequencing, is the cytogenetic analysis still important in polycythemia vera?

South Asian Journal of Cancer ♦ Volume 6 ♦ Issue 2 ♦ April-June 2017 46 showed 19% breast carcinoma with polysomy 17. When we applied 2013 CAP scoring criteria, we found 14.6% increase in number for HER2 amplification with polysomy 17. As we shown one case in Figure 1, polysomy17 with negative according to CAP 2007 guideline but when we applied 2013 CAP guideline on the same case, the case should be given positive with polysomy. When we re-evaluated the 82 cases that were HER2 nonamplified and polysomy 17 accompanied, we found that 12 (14.6%) cases could be defined as HER2 amplified. These 14.6% patients showed HER2 amplification may be suitable for anti-HER2 targeted therapy. There was a significant increase in the number of HER2 amplified cases, i.e., cases increase from 192 to 246 out of 557 cases. As recent study suggested that the presence of CEP17 alterations could identify a more aggressive subset of breast cancers that are nonresponsive to conventional therapy independently of HER2 amplification status.[7] Some researchers believe that polysomy 17 without HER2 amplification do not predict response to lapatinib in metastatic breast cancer.[7] Conclusion FISH results were evaluated (IHC2+ interpreted according to CAP 2007 guideline) with both 2007 and 2013 ASCO/ CAP scoring criteria, we identified significantly more HER2 positive cases as compared to cases evaluated using the 2007 criteria (P < 0.05). Polysomy of CEP17 is a crucial cause of misinterpretation of HER2 FISH result. Using the 2013 ASCO/ CAP scoring criteria on IHC2+ cases evaluate significantly higher in a number of HER2 amplification with polysomy of chromosome 17, which shows more patients appropriate for targeted treatment.